期刊
CANCER CELL
卷 38, 期 4, 页码 433-437出版社
CELL PRESS
DOI: 10.1016/j.ccell.2020.09.003
关键词
-
资金
- National Institute of Aging [R01-AG067548, U01-AG066099]
- CourtenayC
- Lucy PattenDavis Endowed Chair inLungCancerResearch
- Francis Crick Institute
- Cancer Research UK [FC001169]
- UK Medical Research Council [FC001169]
- Wellcome Trust [FC001169]
- Cancer Research UK (TRACERx)
- Cancer Research UK (PEACE)
- Cancer Research UK (Cancer Research UK Cancer Immunotherapy Catalyst Network)
- Cancer Research UK Lung Cancer Centre of Excellence
- Rosetrees Trust
- NovoNordisk Foundation [16584]
- Breast Cancer Research Foundation (BCRF)
- Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant [SU2CAACR-DT23-17]
- American Association for Cancer Research, the scientific partner of SU2C
- European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/2007-2013) Consolidator Grant (FP7-THESEUS) [617844]
- European Commission ITN(FP7-PloidyNet) [607722]
- ERC Advanced Grant (PROTEUS) from the European ResearchCouncil under the European Union's Horizon 2020 Research and Innovation Program [835297]
- Chromavision from the EuropeanUnion'sHorizon 2020ResearchandInnovation Program [665233]
Screening leads to meaningful reductions in deaths from cancers. However, reductions in all-cause mortality (ACM) are harder to demonstrate. Failure to demonstrate ACM benefit should not diminish advances in cancer screening. We consider how co-morbidities related to an aging and damaged soma can hinder achievement of ACM benefit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
